Take Homes in Psoriasis

Take Homes in Psoriasis

Source:

Armstrong A, et al. Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 Study. Presented at: AAD VMX 2021; April 23-25, 2021 (Virtual).

Disclosures: Armstrong reports she is a research investigator and scientific advisor to AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo, Lilly, Menlo, Merck, Modernizing Medicine, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi and Modmed.
May 10, 2021
1 min watch
Save

VIDEO: POETYK-PSO trials show promise of deucravacitinib in plaque psoriasis

Source:

Armstrong A, et al. Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 Study. Presented at: AAD VMX 2021; April 23-25, 2021 (Virtual).

Disclosures: Armstrong reports she is a research investigator and scientific advisor to AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo, Lilly, Menlo, Merck, Modernizing Medicine, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi and Modmed.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, spoke with Healio about the results and clinical implications of the POETYK PSO-1 and POETYK PSO-2 trials.

The late-breaking data, which Armstrong presented at AAD VMX 2021, demonstrated the superiority of deucravacitinib, compared with placebo and apremilast, in improving moderate to severe plaque psoriasis. Specifically, in both studies, she said more patients assigned deucravacitinib vs. placebo or apremilast achieved Psoriasis Area and Severity Index 75. The co-primary endpoint of static Physician’s Global Assessment score of 0/1was also met, according to Armstrong.

The phase 3 study results also indicated that the drug was well tolerated, she noted.

“I feel very excited and encouraged that we will have this new oral option for our patients with moderate to severe plaque psoriasis where we don’t have to trade off efficacy and safety,” Armstrong said.